Cargando…
Treatment of adult metachromatic leukodystrophy model mice using intrathecal administration of type 9 AAV vector encoding arylsulfatase A
Metachromatic leukodystrophy (MLD) is a lysosomal storage disease caused by an arylsulfatase A (ARSA) deficiency and characterized by severe neurological symptoms resulting from demyelination within the central and peripheral nervous systems. We investigated the feasibility and efficacy of intrathec...
Autores principales: | Miyake, Noriko, Miyake, Koichi, Sakai, Atsushi, Yamamoto, Motoko, Suzuki, Hidenori, Shimada, Takashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521568/ https://www.ncbi.nlm.nih.gov/pubmed/34654893 http://dx.doi.org/10.1038/s41598-021-99979-2 |
Ejemplares similares
-
Enzyme replacement in the CSF to treat metachromatic leukodystrophy in mouse model using single intracerebroventricular injection of self-complementary AAV1 vector
por: Hironaka, Kohei, et al.
Publicado: (2015) -
Pharmacokinetic Modeling of Intrathecally Administered Recombinant Human Arylsulfatase A (TAK‐611) in Children With Metachromatic Leukodystrophy
por: Troy, Steven, et al.
Publicado: (2020) -
Intrathecal baclofen in metachromatic leukodystrophy
por: van der Veldt, Nikki, et al.
Publicado: (2018) -
Intravenous arylsulfatase A in metachromatic leukodystrophy: a phase 1/2 study
por: í Dali, Christine, et al.
Publicado: (2020) -
Three novel variants in the arylsulfatase A (ARSA) gene in patients with metachromatic leukodystrophy (MLD)
por: Hettiarachchi, D., et al.
Publicado: (2019)